Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Adherium Ltd. ( (AU:ADR) ) is now available.
Adherium Limited has completed a capital raising via the issue of 436,729,824 fully paid ordinary shares at AUD$0.003 each to sophisticated and institutional investors. The placement, conducted without a prospectus under Australian corporate law provisions, is supported by a cleansing notice confirming the company’s compliance with financial reporting and disclosure obligations, which helps maintain secondary market liquidity and regulatory transparency for existing and new shareholders.
By confirming that there is no excluded information and that it meets continuous disclosure requirements, Adherium reinforces its governance standing in the market. The move strengthens the company’s capital position, potentially providing additional funding capacity for its digital respiratory health operations and product development, while signalling ongoing institutional interest in its business despite the low issue price.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is an Australian-listed medical technology company focused on digital health solutions for respiratory care. It develops and supplies connected medication monitoring devices and platforms aimed at improving adherence and outcomes for patients, and markets its products to institutional and sophisticated healthcare investors and partners.
Technical Sentiment Signal: Sell
Current Market Cap: A$21.64M
See more insights into ADR stock on TipRanks’ Stock Analysis page.